Clinical Trial Update: Bevacizumab in Recurrent Grade II and III Glioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating bevacizumab for recurrent grade II and III glioma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors
• Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Central Nervous System Tumors | Phase 2 | Status: COMPLETED